ストックスクリーナーアプリを入手
9.835
1.45%
-0.145
Greenwich Lifesciences Inc (GLSI) 最新ニュース
HC Wainwright Issues Pessimistic Estimate for GLSI Earnings - Defense World
Greenwich LifeSciences (NASDAQ:GLSI) Price Target Raised to $39.00 at HC Wainwright - Defense World
Greenwich LifeSciences stock target raised to $39 at H.C. Wainwright By Investing.com - Investing.com Canada
H.C. Wainwright Boosts Greenwich LifeSciences (GLSI) Price Target Amid Promising Trial Results | GLSI Stock News - GuruFocus
(GLSI) Proactive Strategies - news.stocktradersdaily.com
Greenwich Lifesciences Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Greenwich LifeSciences, Inc. SEC 10-K Report - TradingView
Greenwich LifeSciences (GLSI) Expected to Announce Earnings on Monday - Defense World
GREENWICH LIFESCIENCES Earnings Preview: Recent $GLSI Insider Trading, Hedge Fund Activity, and More - Nasdaq
Greenwich Lifesciences Inc expected to post a loss of 21 cents a shareEarnings Preview - TradingView
Greenwich Lifesciences CEO Snehal Patel acquires $32,760 in stock - Investing.com
Greenwich Lifesciences CEO Snehal Patel acquires $32,760 in stock By Investing.com - Investing.com UK
Greenwich LifeSciences CEO Snehal Patel buys $48,015 in common stock By Investing.com - Investing.com Canada
Greenwich LifeSciences CEO Snehal Patel buys $48,015 in common stock - Investing.com Australia
Investigative Agent Elicits Responses in Phase 3 Breast Cancer Trial - Curetoday
Greenwich LifeSciences reports progress on FLAMINGO-01 trial By Investing.com - Investing.com South Africa
GLSI stock touches 52-week low at $9.05 amid market challenges By Investing.com - Investing.com South Africa
GLSI stock touches 52-week low at $9.05 amid market challenges - Investing.com
Greenwich Lifesciences Provides Global Update On Flamingo-01 - marketscreener.com
Greenwich LifeSciences Provides Global Update on FLAMINGO-01 - GlobeNewswire
Greenwich LifeSciences reports progress on FLAMINGO-01 trial - Investing.com
Major Breakthrough: Cancer Prevention Trial Reports Positive Data, Elite Hospitals Join - Stock Titan
Greenwich LifeSciences (GLSI) Shares Surge on Positive Phase 3 D - GuruFocus
Flamingo cancer vaccine in phase III pink, Greenwich time nigh? - BioWorld MedTech
12 Health Care Stocks Moving In Wednesday's Pre-Market Session - Benzinga
Greenwich LifeSciences stock rises on cancer shot data (GLSI) - Seeking Alpha
Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial - The Manila Times
Greenwich Lifesciences Announces Positive Immune Response Data From FLAMINGO-01 Phase III Clinical Trial - MarketScreener
Clinical Trial Success: GLSI's Breast Cancer Therapy Shows Promising Results in Expanded Patient Group - Stock Titan
Greenwich LifeSciences (NASDAQ:GLSI) Trading Down 6.7%Time to Sell? - MarketBeat
Recent 15% decline may not have gone down well with Greenwich LifeSciences, Inc. (NASDAQ:GLSI) insiders who've been purchasing recently - simplywall.st
Greenwich LifeSciences Delays Yearly Report Filing - TipRanks
How To Trade (GLSI) - news.stocktradersdaily.com
Greenwich LifeSciences Extends Lock-Up Period for Directors, Officers to March 2026 - MarketScreener
Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026 - GlobeNewswire
Major Insider Confidence Signal: Greenwich LifeSciences Leadership Locks Shares Until 2026 - Stock Titan
HER2-Positive Breast Cancer Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Roche Pharma AG, Dizal Pharma, Greenwich LifeSciences, Ambrx, Alteogen - Barchart
HER2-Positive Breast Cancer Pipeline 2025: Therapies, MOA - openPR.com
GLSI stock touches 52-week low at $10.52 amid market challenges - Investing.com
Greenwich LifeSciences gets DSMB approval to continue late-stage trial of GLSI-100 - MSN
Greenwich LifeSciences Says Preliminary Safety Data for Breast Cancer Therapy Appears Consistent With Prior Trials - Marketscreener.com
Greenwich LifeSciences reports positive safety data on GLSI-100 - Investing.com India
Greenwich LifeSciences reports positive safety data on GLSI-100 By Investing.com - Investing.com UK
Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01 - GlobeNewswire
Trading (GLSI) With Integrated Risk Controls - news.stocktradersdaily.com
Non-Small Cell Lung Cancer Clinical Trial Pipeline | 100+ Companies Pioneering the Future of Treatment - openPR
55% of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) is owned by insiders, and they've been buying recently - Yahoo Finance
Learn to Evaluate (GLSI) using the Charts - news.stocktradersdaily.com
Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Sees Large Increase in Short Interest - MarketBeat
Short Interest in Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Increases By 5.1% - MarketBeat
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Verra Mobility Corporation (NASDAQ: VRRM) - PR Newswire
Pre-market Movers: TNXP, INBS, SMMT, NDRA... - RTTNews
0.63%
大文字化:
|
ボリューム (24 時間):